Lantheus Holdings, Inc. (NASDAQ:LNTH) is Private Capital Management LLC’s 3rd Largest Position

Private Capital Management LLC cut its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 3.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 517,418 shares of the medical equipment provider’s stock after selling 17,975 shares during the period. Lantheus comprises about 11.3% of Private Capital Management LLC’s investment portfolio, making the stock its 3rd biggest position. Private Capital Management LLC owned approximately 0.74% of Lantheus worth $56,787,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Groupama Asset Managment bought a new position in shares of Lantheus in the third quarter worth about $439,000. Swedbank AB increased its holdings in Lantheus by 53.3% in the 4th quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after acquiring an additional 385,000 shares in the last quarter. Janus Henderson Group PLC raised its stake in Lantheus by 7.7% during the 3rd quarter. Janus Henderson Group PLC now owns 3,588,571 shares of the medical equipment provider’s stock worth $393,844,000 after acquiring an additional 257,022 shares during the period. Massachusetts Financial Services Co. MA purchased a new position in Lantheus during the third quarter valued at approximately $25,955,000. Finally, Point72 DIFC Ltd bought a new position in shares of Lantheus in the third quarter worth approximately $23,001,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Lantheus

In other news, Director James H. Thrall sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares of the company’s stock, valued at approximately $3,146,695.32. This represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 1.50% of the company’s stock.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $91.49 on Friday. Lantheus Holdings, Inc. has a 1-year low of $56.44 and a 1-year high of $126.89. The business’s 50 day moving average is $89.80 and its two-hundred day moving average is $96.75. The stock has a market capitalization of $6.36 billion, a P/E ratio of 15.22 and a beta of 0.44.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing the consensus estimate of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, equities research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on LNTH shares. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. Truist Financial boosted their price objective on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, JMP Securities reissued a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $132.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.